nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—STK10—testicular cancer	0.562	1	CbGaD
Vandetanib—ABCC1—Dactinomycin—testicular cancer	0.0309	0.151	CbGbCtD
Vandetanib—ABCC1—Epirubicin—testicular cancer	0.0224	0.109	CbGbCtD
Vandetanib—ABCG2—Dactinomycin—testicular cancer	0.0207	0.101	CbGbCtD
Vandetanib—ABCC1—Vinblastine—testicular cancer	0.0194	0.0945	CbGbCtD
Vandetanib—ABCC1—Etoposide—testicular cancer	0.0174	0.0851	CbGbCtD
Vandetanib—ABCG2—Carboplatin—testicular cancer	0.0139	0.0678	CbGbCtD
Vandetanib—ABCC1—Doxorubicin—testicular cancer	0.0119	0.058	CbGbCtD
Vandetanib—ABCG2—Cisplatin—testicular cancer	0.0119	0.058	CbGbCtD
Vandetanib—ABCG2—Etoposide—testicular cancer	0.0117	0.0569	CbGbCtD
Vandetanib—ABCC1—Methotrexate—testicular cancer	0.0115	0.0562	CbGbCtD
Vandetanib—ABCG2—Doxorubicin—testicular cancer	0.00796	0.0388	CbGbCtD
Vandetanib—ABCG2—Methotrexate—testicular cancer	0.00771	0.0376	CbGbCtD
Vandetanib—ALB—Methotrexate—testicular cancer	0.00532	0.0259	CbGbCtD
Vandetanib—CYP3A4—Ifosfamide—testicular cancer	0.00528	0.0257	CbGbCtD
Vandetanib—CYP3A4—Vinblastine—testicular cancer	0.0028	0.0137	CbGbCtD
Vandetanib—CYP3A4—Etoposide—testicular cancer	0.00252	0.0123	CbGbCtD
Vandetanib—Erlotinib—STK10—testicular cancer	0.00242	0.446	CrCbGaD
Vandetanib—CYP3A4—Doxorubicin—testicular cancer	0.00172	0.00839	CbGbCtD
Vandetanib—Gefitinib—STK10—testicular cancer	0.00152	0.279	CrCbGaD
Vandetanib—Bosutinib—STK10—testicular cancer	0.00149	0.275	CrCbGaD
Vandetanib—FLT4—embryo—testicular cancer	0.000963	0.0146	CbGeAlD
Vandetanib—ERBB3—embryo—testicular cancer	0.000916	0.0139	CbGeAlD
Vandetanib—EPHA6—gonad—testicular cancer	0.000912	0.0138	CbGeAlD
Vandetanib—PLK4—gonad—testicular cancer	0.000901	0.0137	CbGeAlD
Vandetanib—RIPK2—seminal vesicle—testicular cancer	0.000899	0.0137	CbGeAlD
Vandetanib—PTK6—female gonad—testicular cancer	0.000889	0.0135	CbGeAlD
Vandetanib—IRAK4—seminal vesicle—testicular cancer	0.000878	0.0133	CbGeAlD
Vandetanib—FGR—embryo—testicular cancer	0.00085	0.0129	CbGeAlD
Vandetanib—RET—embryo—testicular cancer	0.00085	0.0129	CbGeAlD
Vandetanib—TYRO3—gonad—testicular cancer	0.000846	0.0128	CbGeAlD
Vandetanib—LTK—testis—testicular cancer	0.000822	0.0125	CbGeAlD
Vandetanib—FGR—seminal vesicle—testicular cancer	0.000798	0.0121	CbGeAlD
Vandetanib—FYN—embryo—testicular cancer	0.000792	0.012	CbGeAlD
Vandetanib—EPHA8—testis—testicular cancer	0.000788	0.012	CbGeAlD
Vandetanib—TEK—embryo—testicular cancer	0.000774	0.0118	CbGeAlD
Vandetanib—SLK—seminal vesicle—testicular cancer	0.000765	0.0116	CbGeAlD
Vandetanib—FYN—seminal vesicle—testicular cancer	0.000744	0.0113	CbGeAlD
Vandetanib—MAP4K5—seminal vesicle—testicular cancer	0.000727	0.011	CbGeAlD
Vandetanib—FLT3—gonad—testicular cancer	0.000719	0.0109	CbGeAlD
Vandetanib—STK35—gonad—testicular cancer	0.000705	0.0107	CbGeAlD
Vandetanib—EPHB6—seminal vesicle—testicular cancer	0.000695	0.0106	CbGeAlD
Vandetanib—SRC—embryo—testicular cancer	0.000688	0.0104	CbGeAlD
Vandetanib—TYRO3—female gonad—testicular cancer	0.000688	0.0104	CbGeAlD
Vandetanib—BMPR1B—female gonad—testicular cancer	0.000674	0.0102	CbGeAlD
Vandetanib—YES1—seminal vesicle—testicular cancer	0.000672	0.0102	CbGeAlD
Vandetanib—EPHA6—testis—testicular cancer	0.000657	0.00998	CbGeAlD
Vandetanib—PLK4—testis—testicular cancer	0.000649	0.00986	CbGeAlD
Vandetanib—KDR—embryo—testicular cancer	0.000633	0.00961	CbGeAlD
Vandetanib—TYRO3—testis—testicular cancer	0.00061	0.00926	CbGeAlD
Vandetanib—BLK—lymph node—testicular cancer	0.000603	0.00915	CbGeAlD
Vandetanib—BMPR1B—testis—testicular cancer	0.000597	0.00907	CbGeAlD
Vandetanib—MAP3K19—testis—testicular cancer	0.000597	0.00907	CbGeAlD
Vandetanib—LTK—lymph node—testicular cancer	0.000596	0.00905	CbGeAlD
Vandetanib—KDR—seminal vesicle—testicular cancer	0.000594	0.00902	CbGeAlD
Vandetanib—MAP2K5—seminal vesicle—testicular cancer	0.000594	0.00902	CbGeAlD
Vandetanib—FLT3—female gonad—testicular cancer	0.000585	0.00888	CbGeAlD
Vandetanib—MKNK1—gonad—testicular cancer	0.000584	0.00887	CbGeAlD
Vandetanib—AXL—gonad—testicular cancer	0.000575	0.00872	CbGeAlD
Vandetanib—STK35—female gonad—testicular cancer	0.000573	0.00869	CbGeAlD
Vandetanib—ABL2—female gonad—testicular cancer	0.000558	0.00847	CbGeAlD
Vandetanib—PDGFRB—embryo—testicular cancer	0.000548	0.00831	CbGeAlD
Vandetanib—EGFR—female gonad—testicular cancer	0.000545	0.00827	CbGeAlD
Vandetanib—FLT4—female gonad—testicular cancer	0.000531	0.00806	CbGeAlD
Vandetanib—RIPK2—female gonad—testicular cancer	0.000528	0.00802	CbGeAlD
Vandetanib—VEGFA—female gonad—testicular cancer	0.000527	0.008	CbGeAlD
Vandetanib—MAP4K5—gonad—testicular cancer	0.000526	0.00798	CbGeAlD
Vandetanib—FMO1—female gonad—testicular cancer	0.000524	0.00795	CbGeAlD
Vandetanib—FLT3—testis—testicular cancer	0.000519	0.00787	CbGeAlD
Vandetanib—IRAK4—female gonad—testicular cancer	0.000516	0.00783	CbGeAlD
Vandetanib—PDGFRB—seminal vesicle—testicular cancer	0.000514	0.00781	CbGeAlD
Vandetanib—STK35—testis—testicular cancer	0.000508	0.00771	CbGeAlD
Vandetanib—ERBB3—female gonad—testicular cancer	0.000506	0.00767	CbGeAlD
Vandetanib—ABL2—testis—testicular cancer	0.000495	0.00752	CbGeAlD
Vandetanib—ERBB3—Podofilox—Etoposide—testicular cancer	0.00049	0.191	CbGdCrCtD
Vandetanib—ABL1—embryo—testicular cancer	0.000488	0.00741	CbGeAlD
Vandetanib—YES1—gonad—testicular cancer	0.000485	0.00737	CbGeAlD
Vandetanib—EGFR—testis—testicular cancer	0.000483	0.00734	CbGeAlD
Vandetanib—STK10—gonad—testicular cancer	0.000481	0.0073	CbGeAlD
Vandetanib—MKNK1—female gonad—testicular cancer	0.000475	0.0072	CbGeAlD
Vandetanib—FLT4—testis—testicular cancer	0.000471	0.00715	CbGeAlD
Vandetanib—PLK4—lymph node—testicular cancer	0.000471	0.00714	CbGeAlD
Vandetanib—LCK—female gonad—testicular cancer	0.000469	0.00712	CbGeAlD
Vandetanib—FGR—female gonad—testicular cancer	0.000469	0.00712	CbGeAlD
Vandetanib—RIPK2—testis—testicular cancer	0.000468	0.00711	CbGeAlD
Vandetanib—VEGFA—testis—testicular cancer	0.000467	0.00709	CbGeAlD
Vandetanib—AXL—female gonad—testicular cancer	0.000467	0.00709	CbGeAlD
Vandetanib—SRC—gonad—testicular cancer	0.000467	0.00709	CbGeAlD
Vandetanib—ABL1—seminal vesicle—testicular cancer	0.000459	0.00696	CbGeAlD
Vandetanib—IRAK4—testis—testicular cancer	0.000457	0.00694	CbGeAlD
Vandetanib—SLK—female gonad—testicular cancer	0.000449	0.00682	CbGeAlD
Vandetanib—ERBB3—testis—testicular cancer	0.000448	0.00681	CbGeAlD
Vandetanib—FYN—female gonad—testicular cancer	0.000437	0.00663	CbGeAlD
Vandetanib—BMPR1B—lymph node—testicular cancer	0.000433	0.00657	CbGeAlD
Vandetanib—MAP4K5—female gonad—testicular cancer	0.000427	0.00648	CbGeAlD
Vandetanib—TEK—female gonad—testicular cancer	0.000427	0.00648	CbGeAlD
Vandetanib—MKNK1—testis—testicular cancer	0.000421	0.00639	CbGeAlD
Vandetanib—LCK—testis—testicular cancer	0.000416	0.00631	CbGeAlD
Vandetanib—FGR—testis—testicular cancer	0.000416	0.00631	CbGeAlD
Vandetanib—RET—testis—testicular cancer	0.000416	0.00631	CbGeAlD
Vandetanib—AXL—testis—testicular cancer	0.000414	0.00629	CbGeAlD
Vandetanib—EPHB6—female gonad—testicular cancer	0.000408	0.0062	CbGeAlD
Vandetanib—FMO3—testis—testicular cancer	0.000402	0.0061	CbGeAlD
Vandetanib—SLK—testis—testicular cancer	0.000399	0.00605	CbGeAlD
Vandetanib—YES1—female gonad—testicular cancer	0.000394	0.00599	CbGeAlD
Vandetanib—STK10—female gonad—testicular cancer	0.000391	0.00593	CbGeAlD
Vandetanib—FYN—testis—testicular cancer	0.000388	0.00588	CbGeAlD
Vandetanib—SRC—female gonad—testicular cancer	0.000379	0.00576	CbGeAlD
Vandetanib—TEK—testis—testicular cancer	0.000379	0.00575	CbGeAlD
Vandetanib—MAP4K5—testis—testicular cancer	0.000379	0.00575	CbGeAlD
Vandetanib—FLT3—lymph node—testicular cancer	0.000376	0.00571	CbGeAlD
Vandetanib—PLK4—Teniposide—Etoposide—testicular cancer	0.000375	0.146	CbGdCrCtD
Vandetanib—PDGFRB—gonad—testicular cancer	0.000372	0.00564	CbGeAlD
Vandetanib—STK35—lymph node—testicular cancer	0.000368	0.00559	CbGeAlD
Vandetanib—EPHB6—testis—testicular cancer	0.000362	0.00549	CbGeAlD
Vandetanib—ABL2—lymph node—testicular cancer	0.000359	0.00545	CbGeAlD
Vandetanib—EGFR—lymph node—testicular cancer	0.00035	0.00532	CbGeAlD
Vandetanib—YES1—testis—testicular cancer	0.00035	0.00531	CbGeAlD
Vandetanib—ABCC1—seminal vesicle—testicular cancer	0.000349	0.0053	CbGeAlD
Vandetanib—KDR—female gonad—testicular cancer	0.000349	0.0053	CbGeAlD
Vandetanib—MAP2K5—female gonad—testicular cancer	0.000349	0.0053	CbGeAlD
Vandetanib—STK10—testis—testicular cancer	0.000347	0.00526	CbGeAlD
Vandetanib—FLT4—lymph node—testicular cancer	0.000341	0.00518	CbGeAlD
Vandetanib—RIPK2—lymph node—testicular cancer	0.00034	0.00515	CbGeAlD
Vandetanib—VEGFA—lymph node—testicular cancer	0.000339	0.00514	CbGeAlD
Vandetanib—FMO1—lymph node—testicular cancer	0.000337	0.00511	CbGeAlD
Vandetanib—SRC—testis—testicular cancer	0.000337	0.00511	CbGeAlD
Vandetanib—IRAK4—lymph node—testicular cancer	0.000332	0.00503	CbGeAlD
Vandetanib—ABL1—gonad—testicular cancer	0.000331	0.00503	CbGeAlD
Vandetanib—ERBB3—lymph node—testicular cancer	0.000325	0.00493	CbGeAlD
Vandetanib—MAP2K5—testis—testicular cancer	0.00031	0.0047	CbGeAlD
Vandetanib—KDR—testis—testicular cancer	0.00031	0.0047	CbGeAlD
Vandetanib—MKNK1—lymph node—testicular cancer	0.000305	0.00463	CbGeAlD
Vandetanib—PDGFRB—female gonad—testicular cancer	0.000302	0.00459	CbGeAlD
Vandetanib—RET—lymph node—testicular cancer	0.000301	0.00458	CbGeAlD
Vandetanib—LCK—lymph node—testicular cancer	0.000301	0.00458	CbGeAlD
Vandetanib—FGR—lymph node—testicular cancer	0.000301	0.00458	CbGeAlD
Vandetanib—AXL—lymph node—testicular cancer	0.0003	0.00456	CbGeAlD
Vandetanib—FMO3—lymph node—testicular cancer	0.000291	0.00442	CbGeAlD
Vandetanib—ABCG2—seminal vesicle—testicular cancer	0.000289	0.00439	CbGeAlD
Vandetanib—SLK—lymph node—testicular cancer	0.000289	0.00439	CbGeAlD
Vandetanib—FYN—lymph node—testicular cancer	0.000281	0.00426	CbGeAlD
Vandetanib—MAP4K5—lymph node—testicular cancer	0.000275	0.00417	CbGeAlD
Vandetanib—TEK—lymph node—testicular cancer	0.000275	0.00417	CbGeAlD
Vandetanib—ABL1—female gonad—testicular cancer	0.000269	0.00409	CbGeAlD
Vandetanib—PDGFRB—testis—testicular cancer	0.000268	0.00407	CbGeAlD
Vandetanib—EPHB6—lymph node—testicular cancer	0.000262	0.00398	CbGeAlD
Vandetanib—YES1—lymph node—testicular cancer	0.000254	0.00385	CbGeAlD
Vandetanib—STK10—lymph node—testicular cancer	0.000251	0.00381	CbGeAlD
Vandetanib—SRC—lymph node—testicular cancer	0.000244	0.0037	CbGeAlD
Vandetanib—ABL1—testis—testicular cancer	0.000239	0.00363	CbGeAlD
Vandetanib—MAP2K5—lymph node—testicular cancer	0.000224	0.00341	CbGeAlD
Vandetanib—KDR—lymph node—testicular cancer	0.000224	0.00341	CbGeAlD
Vandetanib—ALB—testis—testicular cancer	0.00022	0.00335	CbGeAlD
Vandetanib—ABCC1—female gonad—testicular cancer	0.000205	0.00311	CbGeAlD
Vandetanib—PLK4—Idarubicin—Epirubicin—testicular cancer	0.000196	0.0762	CbGdCrCtD
Vandetanib—PLK4—Doxorubicin—Epirubicin—testicular cancer	0.000196	0.0762	CbGdCrCtD
Vandetanib—PDGFRB—lymph node—testicular cancer	0.000194	0.00295	CbGeAlD
Vandetanib—ORM1—lymph node—testicular cancer	0.000182	0.00277	CbGeAlD
Vandetanib—ABCC1—testis—testicular cancer	0.000182	0.00276	CbGeAlD
Vandetanib—PLK4—Epirubicin—Doxorubicin—testicular cancer	0.000181	0.0705	CbGdCrCtD
Vandetanib—PLK4—Idarubicin—Doxorubicin—testicular cancer	0.000181	0.0705	CbGdCrCtD
Vandetanib—ABL1—lymph node—testicular cancer	0.000173	0.00263	CbGeAlD
Vandetanib—ABCG2—female gonad—testicular cancer	0.00017	0.00258	CbGeAlD
Vandetanib—ABL1—Daunorubicin—Epirubicin—testicular cancer	0.000165	0.0641	CbGdCrCtD
Vandetanib—ABL1—Doxorubicin—Epirubicin—testicular cancer	0.000165	0.0641	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Epirubicin—testicular cancer	0.000165	0.0641	CbGdCrCtD
Vandetanib—ALB—lymph node—testicular cancer	0.00016	0.00243	CbGeAlD
Vandetanib—ABL1—Epirubicin—Doxorubicin—testicular cancer	0.000152	0.0593	CbGdCrCtD
Vandetanib—ABL1—Idarubicin—Doxorubicin—testicular cancer	0.000152	0.0593	CbGdCrCtD
Vandetanib—ABL1—Daunorubicin—Doxorubicin—testicular cancer	0.000152	0.0593	CbGdCrCtD
Vandetanib—ABCG2—testis—testicular cancer	0.000151	0.00229	CbGeAlD
Vandetanib—ABCC1—lymph node—testicular cancer	0.000132	0.002	CbGeAlD
Vandetanib—ABCG2—lymph node—testicular cancer	0.000109	0.00166	CbGeAlD
Vandetanib—Gastrointestinal disorder—Cisplatin—testicular cancer	7.5e-05	0.000861	CcSEcCtD
Vandetanib—Vomiting—Bleomycin—testicular cancer	7.5e-05	0.000861	CcSEcCtD
Vandetanib—Infestation NOS—Methotrexate—testicular cancer	7.48e-05	0.000858	CcSEcCtD
Vandetanib—Infestation—Methotrexate—testicular cancer	7.48e-05	0.000858	CcSEcCtD
Vandetanib—Depression—Methotrexate—testicular cancer	7.46e-05	0.000856	CcSEcCtD
Vandetanib—Rash—Bleomycin—testicular cancer	7.44e-05	0.000854	CcSEcCtD
Vandetanib—Gastritis—Doxorubicin—testicular cancer	7.44e-05	0.000853	CcSEcCtD
Vandetanib—Pain—Cisplatin—testicular cancer	7.43e-05	0.000853	CcSEcCtD
Vandetanib—Dermatitis—Bleomycin—testicular cancer	7.43e-05	0.000853	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	7.42e-05	0.000851	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	7.41e-05	0.000851	CcSEcCtD
Vandetanib—Renal failure—Methotrexate—testicular cancer	7.35e-05	0.000844	CcSEcCtD
Vandetanib—Neutropenia—Epirubicin—testicular cancer	7.34e-05	0.000842	CcSEcCtD
Vandetanib—Dysuria—Epirubicin—testicular cancer	7.34e-05	0.000842	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Epirubicin—testicular cancer	7.3e-05	0.000837	CcSEcCtD
Vandetanib—Stomatitis—Methotrexate—testicular cancer	7.29e-05	0.000837	CcSEcCtD
Vandetanib—Conjunctivitis—Methotrexate—testicular cancer	7.27e-05	0.000834	CcSEcCtD
Vandetanib—Influenza—Doxorubicin—testicular cancer	7.26e-05	0.000834	CcSEcCtD
Vandetanib—Dysphagia—Doxorubicin—testicular cancer	7.26e-05	0.000834	CcSEcCtD
Vandetanib—Pollakiuria—Epirubicin—testicular cancer	7.25e-05	0.000832	CcSEcCtD
Vandetanib—Asthenia—Ifosfamide—testicular cancer	7.23e-05	0.00083	CcSEcCtD
Vandetanib—Photosensitivity reaction—Epirubicin—testicular cancer	7.17e-05	0.000822	CcSEcCtD
Vandetanib—Paraesthesia—Etoposide—testicular cancer	7.15e-05	0.000821	CcSEcCtD
Vandetanib—Pruritus—Ifosfamide—testicular cancer	7.13e-05	0.000819	CcSEcCtD
Vandetanib—Haematuria—Methotrexate—testicular cancer	7.13e-05	0.000818	CcSEcCtD
Vandetanib—Pancreatitis—Doxorubicin—testicular cancer	7.12e-05	0.000817	CcSEcCtD
Vandetanib—Weight decreased—Epirubicin—testicular cancer	7.1e-05	0.000815	CcSEcCtD
Vandetanib—Dyspnoea—Etoposide—testicular cancer	7.1e-05	0.000815	CcSEcCtD
Vandetanib—Hyperglycaemia—Epirubicin—testicular cancer	7.08e-05	0.000813	CcSEcCtD
Vandetanib—Hepatobiliary disease—Methotrexate—testicular cancer	7.07e-05	0.000812	CcSEcCtD
Vandetanib—Epistaxis—Methotrexate—testicular cancer	7.05e-05	0.00081	CcSEcCtD
Vandetanib—Pneumonia—Epirubicin—testicular cancer	7.04e-05	0.000808	CcSEcCtD
Vandetanib—Nausea—Bleomycin—testicular cancer	7.01e-05	0.000804	CcSEcCtD
Vandetanib—Infestation NOS—Epirubicin—testicular cancer	7e-05	0.000803	CcSEcCtD
Vandetanib—Infestation—Epirubicin—testicular cancer	7e-05	0.000803	CcSEcCtD
Vandetanib—Vomiting—Dactinomycin—testicular cancer	7e-05	0.000803	CcSEcCtD
Vandetanib—Bronchitis—Doxorubicin—testicular cancer	6.99e-05	0.000802	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	6.94e-05	0.000796	CcSEcCtD
Vandetanib—Rash—Dactinomycin—testicular cancer	6.94e-05	0.000796	CcSEcCtD
Vandetanib—Decreased appetite—Etoposide—testicular cancer	6.92e-05	0.000794	CcSEcCtD
Vandetanib—Diarrhoea—Ifosfamide—testicular cancer	6.9e-05	0.000792	CcSEcCtD
Vandetanib—Renal failure—Epirubicin—testicular cancer	6.88e-05	0.00079	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Etoposide—testicular cancer	6.88e-05	0.000789	CcSEcCtD
Vandetanib—Body temperature increased—Cisplatin—testicular cancer	6.87e-05	0.000789	CcSEcCtD
Vandetanib—Fatigue—Etoposide—testicular cancer	6.87e-05	0.000788	CcSEcCtD
Vandetanib—Stomatitis—Epirubicin—testicular cancer	6.82e-05	0.000783	CcSEcCtD
Vandetanib—Pain—Etoposide—testicular cancer	6.81e-05	0.000781	CcSEcCtD
Vandetanib—Constipation—Etoposide—testicular cancer	6.81e-05	0.000781	CcSEcCtD
Vandetanib—Urinary tract infection—Epirubicin—testicular cancer	6.8e-05	0.000781	CcSEcCtD
Vandetanib—Conjunctivitis—Epirubicin—testicular cancer	6.8e-05	0.000781	CcSEcCtD
Vandetanib—Neutropenia—Doxorubicin—testicular cancer	6.79e-05	0.000779	CcSEcCtD
Vandetanib—Dysuria—Doxorubicin—testicular cancer	6.79e-05	0.000779	CcSEcCtD
Vandetanib—Upper respiratory tract infection—Doxorubicin—testicular cancer	6.75e-05	0.000775	CcSEcCtD
Vandetanib—Haemoglobin—Methotrexate—testicular cancer	6.75e-05	0.000774	CcSEcCtD
Vandetanib—Haemorrhage—Methotrexate—testicular cancer	6.71e-05	0.00077	CcSEcCtD
Vandetanib—Pollakiuria—Doxorubicin—testicular cancer	6.71e-05	0.00077	CcSEcCtD
Vandetanib—Haematuria—Epirubicin—testicular cancer	6.67e-05	0.000766	CcSEcCtD
Vandetanib—Dizziness—Ifosfamide—testicular cancer	6.67e-05	0.000765	CcSEcCtD
Vandetanib—Urinary tract disorder—Methotrexate—testicular cancer	6.63e-05	0.000761	CcSEcCtD
Vandetanib—Photosensitivity reaction—Doxorubicin—testicular cancer	6.63e-05	0.000761	CcSEcCtD
Vandetanib—Hepatobiliary disease—Epirubicin—testicular cancer	6.62e-05	0.00076	CcSEcCtD
Vandetanib—Epistaxis—Epirubicin—testicular cancer	6.6e-05	0.000758	CcSEcCtD
Vandetanib—Urethral disorder—Methotrexate—testicular cancer	6.58e-05	0.000755	CcSEcCtD
Vandetanib—Weight decreased—Doxorubicin—testicular cancer	6.57e-05	0.000754	CcSEcCtD
Vandetanib—Sinusitis—Epirubicin—testicular cancer	6.57e-05	0.000754	CcSEcCtD
Vandetanib—Hyperglycaemia—Doxorubicin—testicular cancer	6.55e-05	0.000752	CcSEcCtD
Vandetanib—Nausea—Dactinomycin—testicular cancer	6.54e-05	0.00075	CcSEcCtD
Vandetanib—Pneumonia—Doxorubicin—testicular cancer	6.51e-05	0.000747	CcSEcCtD
Vandetanib—Gastrointestinal pain—Etoposide—testicular cancer	6.51e-05	0.000747	CcSEcCtD
Vandetanib—Infestation NOS—Doxorubicin—testicular cancer	6.48e-05	0.000743	CcSEcCtD
Vandetanib—Infestation—Doxorubicin—testicular cancer	6.48e-05	0.000743	CcSEcCtD
Vandetanib—Visual impairment—Methotrexate—testicular cancer	6.47e-05	0.000742	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	6.42e-05	0.000737	CcSEcCtD
Vandetanib—Vomiting—Ifosfamide—testicular cancer	6.41e-05	0.000736	CcSEcCtD
Vandetanib—Bradycardia—Epirubicin—testicular cancer	6.4e-05	0.000734	CcSEcCtD
Vandetanib—Renal failure—Doxorubicin—testicular cancer	6.37e-05	0.000731	CcSEcCtD
Vandetanib—Rash—Ifosfamide—testicular cancer	6.36e-05	0.00073	CcSEcCtD
Vandetanib—Dermatitis—Ifosfamide—testicular cancer	6.35e-05	0.000729	CcSEcCtD
Vandetanib—Erythema multiforme—Methotrexate—testicular cancer	6.35e-05	0.000728	CcSEcCtD
Vandetanib—Haemoglobin—Epirubicin—testicular cancer	6.32e-05	0.000725	CcSEcCtD
Vandetanib—Stomatitis—Doxorubicin—testicular cancer	6.31e-05	0.000724	CcSEcCtD
Vandetanib—Abdominal pain—Etoposide—testicular cancer	6.3e-05	0.000722	CcSEcCtD
Vandetanib—Body temperature increased—Etoposide—testicular cancer	6.3e-05	0.000722	CcSEcCtD
Vandetanib—Urinary tract infection—Doxorubicin—testicular cancer	6.3e-05	0.000722	CcSEcCtD
Vandetanib—Conjunctivitis—Doxorubicin—testicular cancer	6.3e-05	0.000722	CcSEcCtD
Vandetanib—Haemorrhage—Epirubicin—testicular cancer	6.28e-05	0.000721	CcSEcCtD
Vandetanib—Eye disorder—Methotrexate—testicular cancer	6.27e-05	0.00072	CcSEcCtD
Vandetanib—Asthenia—Cisplatin—testicular cancer	6.24e-05	0.000716	CcSEcCtD
Vandetanib—Cardiac disorder—Methotrexate—testicular cancer	6.23e-05	0.000715	CcSEcCtD
Vandetanib—Urinary tract disorder—Epirubicin—testicular cancer	6.21e-05	0.000712	CcSEcCtD
Vandetanib—Haematuria—Doxorubicin—testicular cancer	6.17e-05	0.000709	CcSEcCtD
Vandetanib—Urethral disorder—Epirubicin—testicular cancer	6.16e-05	0.000707	CcSEcCtD
Vandetanib—Hepatobiliary disease—Doxorubicin—testicular cancer	6.13e-05	0.000703	CcSEcCtD
Vandetanib—Epistaxis—Doxorubicin—testicular cancer	6.11e-05	0.000701	CcSEcCtD
Vandetanib—Angiopathy—Methotrexate—testicular cancer	6.09e-05	0.000699	CcSEcCtD
Vandetanib—Sinusitis—Doxorubicin—testicular cancer	6.08e-05	0.000697	CcSEcCtD
Vandetanib—Visual impairment—Epirubicin—testicular cancer	6.06e-05	0.000695	CcSEcCtD
Vandetanib—Mediastinal disorder—Methotrexate—testicular cancer	6.05e-05	0.000694	CcSEcCtD
Vandetanib—Nausea—Ifosfamide—testicular cancer	5.99e-05	0.000687	CcSEcCtD
Vandetanib—Diarrhoea—Cisplatin—testicular cancer	5.95e-05	0.000683	CcSEcCtD
Vandetanib—Erythema multiforme—Epirubicin—testicular cancer	5.94e-05	0.000682	CcSEcCtD
Vandetanib—Alopecia—Methotrexate—testicular cancer	5.93e-05	0.000681	CcSEcCtD
Vandetanib—Bradycardia—Doxorubicin—testicular cancer	5.92e-05	0.000679	CcSEcCtD
Vandetanib—Mental disorder—Methotrexate—testicular cancer	5.88e-05	0.000675	CcSEcCtD
Vandetanib—Eye disorder—Epirubicin—testicular cancer	5.87e-05	0.000674	CcSEcCtD
Vandetanib—Malnutrition—Methotrexate—testicular cancer	5.84e-05	0.000671	CcSEcCtD
Vandetanib—Haemoglobin—Doxorubicin—testicular cancer	5.84e-05	0.000671	CcSEcCtD
Vandetanib—Cardiac disorder—Epirubicin—testicular cancer	5.83e-05	0.000669	CcSEcCtD
Vandetanib—Haemorrhage—Doxorubicin—testicular cancer	5.81e-05	0.000667	CcSEcCtD
Vandetanib—Urinary tract disorder—Doxorubicin—testicular cancer	5.74e-05	0.000659	CcSEcCtD
Vandetanib—Dysgeusia—Methotrexate—testicular cancer	5.72e-05	0.000657	CcSEcCtD
Vandetanib—Asthenia—Etoposide—testicular cancer	5.71e-05	0.000656	CcSEcCtD
Vandetanib—Angiopathy—Epirubicin—testicular cancer	5.7e-05	0.000654	CcSEcCtD
Vandetanib—Urethral disorder—Doxorubicin—testicular cancer	5.7e-05	0.000654	CcSEcCtD
Vandetanib—Mediastinal disorder—Epirubicin—testicular cancer	5.66e-05	0.00065	CcSEcCtD
Vandetanib—Pruritus—Etoposide—testicular cancer	5.63e-05	0.000647	CcSEcCtD
Vandetanib—Arrhythmia—Epirubicin—testicular cancer	5.61e-05	0.000644	CcSEcCtD
Vandetanib—Visual impairment—Doxorubicin—testicular cancer	5.6e-05	0.000643	CcSEcCtD
Vandetanib—Alopecia—Epirubicin—testicular cancer	5.55e-05	0.000637	CcSEcCtD
Vandetanib—Vomiting—Cisplatin—testicular cancer	5.53e-05	0.000634	CcSEcCtD
Vandetanib—Vision blurred—Methotrexate—testicular cancer	5.51e-05	0.000632	CcSEcCtD
Vandetanib—Mental disorder—Epirubicin—testicular cancer	5.5e-05	0.000632	CcSEcCtD
Vandetanib—Erythema multiforme—Doxorubicin—testicular cancer	5.5e-05	0.000631	CcSEcCtD
Vandetanib—Rash—Cisplatin—testicular cancer	5.48e-05	0.000629	CcSEcCtD
Vandetanib—Dermatitis—Cisplatin—testicular cancer	5.48e-05	0.000628	CcSEcCtD
Vandetanib—Malnutrition—Epirubicin—testicular cancer	5.47e-05	0.000628	CcSEcCtD
Vandetanib—Diarrhoea—Etoposide—testicular cancer	5.45e-05	0.000625	CcSEcCtD
Vandetanib—Eye disorder—Doxorubicin—testicular cancer	5.43e-05	0.000623	CcSEcCtD
Vandetanib—Cardiac disorder—Doxorubicin—testicular cancer	5.4e-05	0.000619	CcSEcCtD
Vandetanib—Dysgeusia—Epirubicin—testicular cancer	5.36e-05	0.000615	CcSEcCtD
Vandetanib—Angiopathy—Doxorubicin—testicular cancer	5.27e-05	0.000605	CcSEcCtD
Vandetanib—Dizziness—Etoposide—testicular cancer	5.27e-05	0.000604	CcSEcCtD
Vandetanib—Muscle spasms—Epirubicin—testicular cancer	5.26e-05	0.000603	CcSEcCtD
Vandetanib—Mediastinal disorder—Doxorubicin—testicular cancer	5.24e-05	0.000601	CcSEcCtD
Vandetanib—Arrhythmia—Doxorubicin—testicular cancer	5.19e-05	0.000596	CcSEcCtD
Vandetanib—Nausea—Cisplatin—testicular cancer	5.16e-05	0.000593	CcSEcCtD
Vandetanib—Vision blurred—Epirubicin—testicular cancer	5.15e-05	0.000592	CcSEcCtD
Vandetanib—Alopecia—Doxorubicin—testicular cancer	5.14e-05	0.00059	CcSEcCtD
Vandetanib—Cough—Methotrexate—testicular cancer	5.1e-05	0.000585	CcSEcCtD
Vandetanib—Mental disorder—Doxorubicin—testicular cancer	5.09e-05	0.000584	CcSEcCtD
Vandetanib—Convulsion—Methotrexate—testicular cancer	5.06e-05	0.000581	CcSEcCtD
Vandetanib—Vomiting—Etoposide—testicular cancer	5.06e-05	0.000581	CcSEcCtD
Vandetanib—Malnutrition—Doxorubicin—testicular cancer	5.06e-05	0.000581	CcSEcCtD
Vandetanib—Rash—Etoposide—testicular cancer	5.02e-05	0.000576	CcSEcCtD
Vandetanib—Dermatitis—Etoposide—testicular cancer	5.02e-05	0.000576	CcSEcCtD
Vandetanib—Headache—Etoposide—testicular cancer	4.99e-05	0.000573	CcSEcCtD
Vandetanib—Arthralgia—Methotrexate—testicular cancer	4.98e-05	0.000571	CcSEcCtD
Vandetanib—Chest pain—Methotrexate—testicular cancer	4.98e-05	0.000571	CcSEcCtD
Vandetanib—Dysgeusia—Doxorubicin—testicular cancer	4.96e-05	0.000569	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	4.94e-05	0.000567	CcSEcCtD
Vandetanib—Muscle spasms—Doxorubicin—testicular cancer	4.87e-05	0.000558	CcSEcCtD
Vandetanib—Loss of consciousness—Epirubicin—testicular cancer	4.81e-05	0.000552	CcSEcCtD
Vandetanib—Cough—Epirubicin—testicular cancer	4.77e-05	0.000548	CcSEcCtD
Vandetanib—Vision blurred—Doxorubicin—testicular cancer	4.77e-05	0.000547	CcSEcCtD
Vandetanib—Convulsion—Epirubicin—testicular cancer	4.74e-05	0.000544	CcSEcCtD
Vandetanib—Infection—Methotrexate—testicular cancer	4.74e-05	0.000544	CcSEcCtD
Vandetanib—Nausea—Etoposide—testicular cancer	4.73e-05	0.000543	CcSEcCtD
Vandetanib—Hypertension—Epirubicin—testicular cancer	4.72e-05	0.000542	CcSEcCtD
Vandetanib—Nervous system disorder—Methotrexate—testicular cancer	4.68e-05	0.000537	CcSEcCtD
Vandetanib—Thrombocytopenia—Methotrexate—testicular cancer	4.67e-05	0.000536	CcSEcCtD
Vandetanib—Arthralgia—Epirubicin—testicular cancer	4.66e-05	0.000534	CcSEcCtD
Vandetanib—Chest pain—Epirubicin—testicular cancer	4.66e-05	0.000534	CcSEcCtD
Vandetanib—Anxiety—Epirubicin—testicular cancer	4.64e-05	0.000533	CcSEcCtD
Vandetanib—Skin disorder—Methotrexate—testicular cancer	4.63e-05	0.000532	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	4.62e-05	0.000531	CcSEcCtD
Vandetanib—Dry mouth—Epirubicin—testicular cancer	4.55e-05	0.000523	CcSEcCtD
Vandetanib—Oedema—Epirubicin—testicular cancer	4.46e-05	0.000512	CcSEcCtD
Vandetanib—Loss of consciousness—Doxorubicin—testicular cancer	4.45e-05	0.00051	CcSEcCtD
Vandetanib—Infection—Epirubicin—testicular cancer	4.43e-05	0.000509	CcSEcCtD
Vandetanib—Cough—Doxorubicin—testicular cancer	4.42e-05	0.000507	CcSEcCtD
Vandetanib—Convulsion—Doxorubicin—testicular cancer	4.39e-05	0.000503	CcSEcCtD
Vandetanib—Nervous system disorder—Epirubicin—testicular cancer	4.38e-05	0.000502	CcSEcCtD
Vandetanib—Thrombocytopenia—Epirubicin—testicular cancer	4.37e-05	0.000502	CcSEcCtD
Vandetanib—Hypertension—Doxorubicin—testicular cancer	4.37e-05	0.000501	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Methotrexate—testicular cancer	4.35e-05	0.000499	CcSEcCtD
Vandetanib—Skin disorder—Epirubicin—testicular cancer	4.34e-05	0.000498	CcSEcCtD
Vandetanib—Insomnia—Methotrexate—testicular cancer	4.31e-05	0.000495	CcSEcCtD
Vandetanib—Arthralgia—Doxorubicin—testicular cancer	4.31e-05	0.000494	CcSEcCtD
Vandetanib—Chest pain—Doxorubicin—testicular cancer	4.31e-05	0.000494	CcSEcCtD
Vandetanib—Anxiety—Doxorubicin—testicular cancer	4.29e-05	0.000493	CcSEcCtD
Vandetanib—Paraesthesia—Methotrexate—testicular cancer	4.28e-05	0.000492	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	4.28e-05	0.000491	CcSEcCtD
Vandetanib—Dyspnoea—Methotrexate—testicular cancer	4.25e-05	0.000488	CcSEcCtD
Vandetanib—Dry mouth—Doxorubicin—testicular cancer	4.21e-05	0.000484	CcSEcCtD
Vandetanib—Dyspepsia—Methotrexate—testicular cancer	4.2e-05	0.000482	CcSEcCtD
Vandetanib—Decreased appetite—Methotrexate—testicular cancer	4.15e-05	0.000476	CcSEcCtD
Vandetanib—Oedema—Doxorubicin—testicular cancer	4.13e-05	0.000474	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Methotrexate—testicular cancer	4.12e-05	0.000473	CcSEcCtD
Vandetanib—Fatigue—Methotrexate—testicular cancer	4.11e-05	0.000472	CcSEcCtD
Vandetanib—Infection—Doxorubicin—testicular cancer	4.1e-05	0.000471	CcSEcCtD
Vandetanib—Pain—Methotrexate—testicular cancer	4.08e-05	0.000468	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Epirubicin—testicular cancer	4.07e-05	0.000467	CcSEcCtD
Vandetanib—Nervous system disorder—Doxorubicin—testicular cancer	4.05e-05	0.000465	CcSEcCtD
Vandetanib—Thrombocytopenia—Doxorubicin—testicular cancer	4.04e-05	0.000464	CcSEcCtD
Vandetanib—Insomnia—Epirubicin—testicular cancer	4.04e-05	0.000463	CcSEcCtD
Vandetanib—Skin disorder—Doxorubicin—testicular cancer	4.01e-05	0.00046	CcSEcCtD
Vandetanib—Paraesthesia—Epirubicin—testicular cancer	4.01e-05	0.00046	CcSEcCtD
Vandetanib—Dyspnoea—Epirubicin—testicular cancer	3.98e-05	0.000457	CcSEcCtD
Vandetanib—Dyspepsia—Epirubicin—testicular cancer	3.93e-05	0.000451	CcSEcCtD
Vandetanib—Gastrointestinal pain—Methotrexate—testicular cancer	3.9e-05	0.000448	CcSEcCtD
Vandetanib—Decreased appetite—Epirubicin—testicular cancer	3.88e-05	0.000445	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Epirubicin—testicular cancer	3.85e-05	0.000442	CcSEcCtD
Vandetanib—Fatigue—Epirubicin—testicular cancer	3.85e-05	0.000442	CcSEcCtD
Vandetanib—Pain—Epirubicin—testicular cancer	3.82e-05	0.000438	CcSEcCtD
Vandetanib—Constipation—Epirubicin—testicular cancer	3.82e-05	0.000438	CcSEcCtD
Vandetanib—Abdominal pain—Methotrexate—testicular cancer	3.77e-05	0.000433	CcSEcCtD
Vandetanib—Body temperature increased—Methotrexate—testicular cancer	3.77e-05	0.000433	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Doxorubicin—testicular cancer	3.76e-05	0.000432	CcSEcCtD
Vandetanib—Insomnia—Doxorubicin—testicular cancer	3.74e-05	0.000429	CcSEcCtD
Vandetanib—Paraesthesia—Doxorubicin—testicular cancer	3.71e-05	0.000426	CcSEcCtD
Vandetanib—Dyspnoea—Doxorubicin—testicular cancer	3.68e-05	0.000423	CcSEcCtD
Vandetanib—Gastrointestinal pain—Epirubicin—testicular cancer	3.65e-05	0.000419	CcSEcCtD
Vandetanib—Dyspepsia—Doxorubicin—testicular cancer	3.64e-05	0.000417	CcSEcCtD
Vandetanib—Decreased appetite—Doxorubicin—testicular cancer	3.59e-05	0.000412	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Doxorubicin—testicular cancer	3.57e-05	0.000409	CcSEcCtD
Vandetanib—Fatigue—Doxorubicin—testicular cancer	3.56e-05	0.000409	CcSEcCtD
Vandetanib—Constipation—Doxorubicin—testicular cancer	3.53e-05	0.000405	CcSEcCtD
Vandetanib—Pain—Doxorubicin—testicular cancer	3.53e-05	0.000405	CcSEcCtD
Vandetanib—Body temperature increased—Epirubicin—testicular cancer	3.53e-05	0.000405	CcSEcCtD
Vandetanib—Abdominal pain—Epirubicin—testicular cancer	3.53e-05	0.000405	CcSEcCtD
Vandetanib—Asthenia—Methotrexate—testicular cancer	3.42e-05	0.000393	CcSEcCtD
Vandetanib—LCK—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	3.42e-05	0.000475	CbGpPWpGaD
Vandetanib—SRC—Signaling by FGFR in disease—KIT—testicular cancer	3.42e-05	0.000474	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—H2AFZ—testicular cancer	3.42e-05	0.000474	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—KITLG—testicular cancer	3.41e-05	0.000474	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—STK11—testicular cancer	3.4e-05	0.000472	CbGpPWpGaD
Vandetanib—SRC—Signaling by EGFR—KIT—testicular cancer	3.39e-05	0.00047	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—INSL3—testicular cancer	3.38e-05	0.000469	CbGpPWpGaD
Vandetanib—Gastrointestinal pain—Doxorubicin—testicular cancer	3.38e-05	0.000388	CcSEcCtD
Vandetanib—Pruritus—Methotrexate—testicular cancer	3.37e-05	0.000387	CcSEcCtD
Vandetanib—SRC—Signaling by EGFR in Cancer—KIT—testicular cancer	3.36e-05	0.000466	CbGpPWpGaD
Vandetanib—SRC—Signaling by PDGF—KIT—testicular cancer	3.34e-05	0.000464	CbGpPWpGaD
Vandetanib—RIPK2—Adaptive Immune System—FGFR3—testicular cancer	3.32e-05	0.00046	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—FGFR3—testicular cancer	3.31e-05	0.00046	CbGpPWpGaD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	3.3e-05	0.000458	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling by NGF—KIT—testicular cancer	3.28e-05	0.000455	CbGpPWpGaD
Vandetanib—Abdominal pain—Doxorubicin—testicular cancer	3.27e-05	0.000375	CcSEcCtD
Vandetanib—Body temperature increased—Doxorubicin—testicular cancer	3.27e-05	0.000375	CcSEcCtD
Vandetanib—Diarrhoea—Methotrexate—testicular cancer	3.26e-05	0.000375	CcSEcCtD
Vandetanib—SRC—Innate Immune System—BCL10—testicular cancer	3.23e-05	0.000448	CbGpPWpGaD
Vandetanib—Asthenia—Epirubicin—testicular cancer	3.2e-05	0.000368	CcSEcCtD
Vandetanib—BLK—Adaptive Immune System—FGFR3—testicular cancer	3.19e-05	0.000443	CbGpPWpGaD
Vandetanib—RIPK2—Innate Immune System—KIT—testicular cancer	3.17e-05	0.00044	CbGpPWpGaD
Vandetanib—FYN—Signaling by NGF—KIT—testicular cancer	3.16e-05	0.000439	CbGpPWpGaD
Vandetanib—Pruritus—Epirubicin—testicular cancer	3.16e-05	0.000362	CcSEcCtD
Vandetanib—Dizziness—Methotrexate—testicular cancer	3.15e-05	0.000362	CcSEcCtD
Vandetanib—FLT4—Signaling Pathways—KITLG—testicular cancer	3.14e-05	0.000436	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—BCL10—testicular cancer	3.1e-05	0.00043	CbGpPWpGaD
Vandetanib—Diarrhoea—Epirubicin—testicular cancer	3.05e-05	0.00035	CcSEcCtD
Vandetanib—RIPK2—Adaptive Immune System—KIT—testicular cancer	3.05e-05	0.000423	CbGpPWpGaD
Vandetanib—ERBB3—Innate Immune System—FGFR3—testicular cancer	3.05e-05	0.000423	CbGpPWpGaD
Vandetanib—FGR—Innate Immune System—KIT—testicular cancer	3.04e-05	0.000422	CbGpPWpGaD
Vandetanib—Vomiting—Methotrexate—testicular cancer	3.03e-05	0.000348	CcSEcCtD
Vandetanib—SRC—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	3.03e-05	0.00042	CbGpPWpGaD
Vandetanib—Rash—Methotrexate—testicular cancer	3.01e-05	0.000345	CcSEcCtD
Vandetanib—Dermatitis—Methotrexate—testicular cancer	3e-05	0.000345	CcSEcCtD
Vandetanib—IRAK4—Immune System—KITLG—testicular cancer	2.99e-05	0.000416	CbGpPWpGaD
Vandetanib—Headache—Methotrexate—testicular cancer	2.99e-05	0.000343	CcSEcCtD
Vandetanib—EGFR—Signaling by NGF—FGFR3—testicular cancer	2.97e-05	0.000413	CbGpPWpGaD
Vandetanib—Asthenia—Doxorubicin—testicular cancer	2.96e-05	0.00034	CcSEcCtD
Vandetanib—Dizziness—Epirubicin—testicular cancer	2.95e-05	0.000339	CcSEcCtD
Vandetanib—BLK—Adaptive Immune System—KIT—testicular cancer	2.93e-05	0.000407	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—FGFR3—testicular cancer	2.93e-05	0.000406	CbGpPWpGaD
Vandetanib—Pruritus—Doxorubicin—testicular cancer	2.92e-05	0.000335	CcSEcCtD
Vandetanib—EGFR—Signaling Pathways—INSL3—testicular cancer	2.92e-05	0.000405	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—FGFR3—testicular cancer	2.87e-05	0.000398	CbGpPWpGaD
Vandetanib—Vomiting—Epirubicin—testicular cancer	2.84e-05	0.000326	CcSEcCtD
Vandetanib—KDR—Developmental Biology—MMP2—testicular cancer	2.84e-05	0.000394	CbGpPWpGaD
Vandetanib—Nausea—Methotrexate—testicular cancer	2.83e-05	0.000325	CcSEcCtD
Vandetanib—MKNK1—Signaling Pathways—H2AFZ—testicular cancer	2.83e-05	0.000393	CbGpPWpGaD
Vandetanib—Diarrhoea—Doxorubicin—testicular cancer	2.83e-05	0.000324	CcSEcCtD
Vandetanib—MKNK1—Signaling Pathways—STK11—testicular cancer	2.82e-05	0.000391	CbGpPWpGaD
Vandetanib—Rash—Epirubicin—testicular cancer	2.81e-05	0.000323	CcSEcCtD
Vandetanib—LCK—Signaling Pathways—INSL3—testicular cancer	2.81e-05	0.00039	CbGpPWpGaD
Vandetanib—Dermatitis—Epirubicin—testicular cancer	2.81e-05	0.000323	CcSEcCtD
Vandetanib—ERBB3—Innate Immune System—KIT—testicular cancer	2.8e-05	0.000388	CbGpPWpGaD
Vandetanib—Headache—Epirubicin—testicular cancer	2.8e-05	0.000321	CcSEcCtD
Vandetanib—AXL—Signaling Pathways—FGFR3—testicular cancer	2.79e-05	0.000388	CbGpPWpGaD
Vandetanib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.78e-05	0.000386	CbGpPWpGaD
Vandetanib—MKNK1—Disease—FGFR3—testicular cancer	2.77e-05	0.000384	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—KITLG—testicular cancer	2.74e-05	0.00038	CbGpPWpGaD
Vandetanib—Dizziness—Doxorubicin—testicular cancer	2.73e-05	0.000313	CcSEcCtD
Vandetanib—EGFR—Signaling by NGF—KIT—testicular cancer	2.73e-05	0.000379	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—KITLG—testicular cancer	2.71e-05	0.000376	CbGpPWpGaD
Vandetanib—ERBB3—Adaptive Immune System—KIT—testicular cancer	2.69e-05	0.000373	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—KITLG—testicular cancer	2.68e-05	0.000372	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—FGFR3—testicular cancer	2.67e-05	0.000371	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—KITLG—testicular cancer	2.67e-05	0.000371	CbGpPWpGaD
Vandetanib—Nausea—Epirubicin—testicular cancer	2.65e-05	0.000304	CcSEcCtD
Vandetanib—PDGFRB—Immune System—BCL10—testicular cancer	2.65e-05	0.000367	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—KITLG—testicular cancer	2.64e-05	0.000367	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—KITLG—testicular cancer	2.63e-05	0.000365	CbGpPWpGaD
Vandetanib—LCK—Signaling by NGF—KIT—testicular cancer	2.63e-05	0.000365	CbGpPWpGaD
Vandetanib—Vomiting—Doxorubicin—testicular cancer	2.63e-05	0.000301	CcSEcCtD
Vandetanib—BLK—Immune System—KITLG—testicular cancer	2.61e-05	0.000362	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—KITLG—testicular cancer	2.61e-05	0.000362	CbGpPWpGaD
Vandetanib—Rash—Doxorubicin—testicular cancer	2.6e-05	0.000299	CcSEcCtD
Vandetanib—Dermatitis—Doxorubicin—testicular cancer	2.6e-05	0.000299	CcSEcCtD
Vandetanib—FGR—Immune System—KITLG—testicular cancer	2.6e-05	0.00036	CbGpPWpGaD
Vandetanib—LYN—Immune System—BCL10—testicular cancer	2.59e-05	0.00036	CbGpPWpGaD
Vandetanib—Headache—Doxorubicin—testicular cancer	2.59e-05	0.000297	CcSEcCtD
Vandetanib—ABL1—Immune System—BCL10—testicular cancer	2.58e-05	0.000358	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—KITLG—testicular cancer	2.58e-05	0.000358	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—MMP2—testicular cancer	2.57e-05	0.000357	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—FGFR3—testicular cancer	2.57e-05	0.000356	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—KIT—testicular cancer	2.56e-05	0.000356	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—MMP2—testicular cancer	2.56e-05	0.000356	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—FGFR3—testicular cancer	2.55e-05	0.000355	CbGpPWpGaD
Vandetanib—FYN—Immune System—BCL10—testicular cancer	2.55e-05	0.000354	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—MMP2—testicular cancer	2.55e-05	0.000354	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—STK11—testicular cancer	2.54e-05	0.000352	CbGpPWpGaD
Vandetanib—MKNK1—Disease—KIT—testicular cancer	2.54e-05	0.000352	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—FGFR3—testicular cancer	2.54e-05	0.000352	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—KITLG—testicular cancer	2.54e-05	0.000352	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—MMP2—testicular cancer	2.53e-05	0.000352	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INSL3—testicular cancer	2.49e-05	0.000345	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—MMP2—testicular cancer	2.46e-05	0.000342	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—KIT—testicular cancer	2.46e-05	0.000341	CbGpPWpGaD
Vandetanib—Nausea—Doxorubicin—testicular cancer	2.45e-05	0.000282	CcSEcCtD
Vandetanib—ERBB3—Disease—H2AFZ—testicular cancer	2.4e-05	0.000333	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—KITLG—testicular cancer	2.39e-05	0.000331	CbGpPWpGaD
Vandetanib—YES1—Adaptive Immune System—KIT—testicular cancer	2.36e-05	0.000327	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—KIT—testicular cancer	2.35e-05	0.000325	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—FGFR3—testicular cancer	2.34e-05	0.000324	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—KIT—testicular cancer	2.33e-05	0.000323	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—KITLG—testicular cancer	2.28e-05	0.000317	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—FGFR3—testicular cancer	2.23e-05	0.000309	CbGpPWpGaD
Vandetanib—ERBB3—Disease—KITLG—testicular cancer	2.2e-05	0.000306	CbGpPWpGaD
Vandetanib—EGFR—Immune System—BCL10—testicular cancer	2.2e-05	0.000306	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—KITLG—testicular cancer	2.2e-05	0.000305	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KITLG—testicular cancer	2.19e-05	0.000304	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—MMP2—testicular cancer	2.19e-05	0.000304	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—KIT—testicular cancer	2.15e-05	0.000298	CbGpPWpGaD
Vandetanib—LCK—Immune System—BCL10—testicular cancer	2.12e-05	0.000295	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KITLG—testicular cancer	2.11e-05	0.000293	CbGpPWpGaD
Vandetanib—YES1—Immune System—KITLG—testicular cancer	2.1e-05	0.000291	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—KIT—testicular cancer	2.04e-05	0.000284	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—FGFR3—testicular cancer	2.04e-05	0.000283	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—FGFR3—testicular cancer	2.01e-05	0.000279	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—FGFR3—testicular cancer	1.99e-05	0.000277	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—FGFR3—testicular cancer	1.98e-05	0.000275	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.98e-05	0.000274	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—FGFR3—testicular cancer	1.96e-05	0.000272	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—FGFR3—testicular cancer	1.96e-05	0.000271	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KITLG—testicular cancer	1.95e-05	0.00027	CbGpPWpGaD
Vandetanib—BLK—Immune System—FGFR3—testicular cancer	1.94e-05	0.000269	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—FGFR3—testicular cancer	1.94e-05	0.000269	CbGpPWpGaD
Vandetanib—FGR—Immune System—FGFR3—testicular cancer	1.93e-05	0.000268	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—FGFR3—testicular cancer	1.92e-05	0.000266	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—H2AFZ—testicular cancer	1.9e-05	0.000264	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—STK11—testicular cancer	1.89e-05	0.000263	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—FGFR3—testicular cancer	1.89e-05	0.000262	CbGpPWpGaD
Vandetanib—SRC—Immune System—BCL10—testicular cancer	1.88e-05	0.000261	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—KIT—testicular cancer	1.87e-05	0.000259	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KITLG—testicular cancer	1.87e-05	0.000259	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MMP2—testicular cancer	1.87e-05	0.000259	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—KIT—testicular cancer	1.85e-05	0.000256	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MMP2—testicular cancer	1.84e-05	0.000255	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—KIT—testicular cancer	1.83e-05	0.000254	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MMP2—testicular cancer	1.83e-05	0.000254	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—KIT—testicular cancer	1.82e-05	0.000253	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MMP2—testicular cancer	1.81e-05	0.000251	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—KIT—testicular cancer	1.8e-05	0.00025	CbGpPWpGaD
Vandetanib—PDGFRB—Adaptive Immune System—KIT—testicular cancer	1.8e-05	0.000249	CbGpPWpGaD
Vandetanib—BLK—Immune System—KIT—testicular cancer	1.78e-05	0.000247	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—KIT—testicular cancer	1.78e-05	0.000247	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—FGFR3—testicular cancer	1.77e-05	0.000246	CbGpPWpGaD
Vandetanib—FGR—Immune System—KIT—testicular cancer	1.77e-05	0.000246	CbGpPWpGaD
Vandetanib—LYN—Adaptive Immune System—KIT—testicular cancer	1.76e-05	0.000244	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KITLG—testicular cancer	1.75e-05	0.000243	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	1.74e-05	0.000242	CbGpPWpGaD
Vandetanib—FYN—Adaptive Immune System—KIT—testicular cancer	1.73e-05	0.00024	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—STK11—testicular cancer	1.73e-05	0.00024	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—H2AFZ—testicular cancer	1.7e-05	0.000235	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—FGFR3—testicular cancer	1.7e-05	0.000235	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—STK11—testicular cancer	1.69e-05	0.000234	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—H2AFZ—testicular cancer	1.68e-05	0.000233	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—STK11—testicular cancer	1.67e-05	0.000232	CbGpPWpGaD
Vandetanib—ERBB3—Disease—FGFR3—testicular cancer	1.64e-05	0.000227	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—FGFR3—testicular cancer	1.63e-05	0.000227	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—KIT—testicular cancer	1.63e-05	0.000226	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	1.63e-05	0.000226	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—HPGDS—testicular cancer	1.62e-05	0.000225	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—H2AFZ—testicular cancer	1.6e-05	0.000222	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	1.6e-05	0.000222	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KITLG—testicular cancer	1.6e-05	0.000221	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—FGFR3—testicular cancer	1.57e-05	0.000218	CbGpPWpGaD
Vandetanib—LYN—Immune System—KITLG—testicular cancer	1.56e-05	0.000217	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MMP2—testicular cancer	1.56e-05	0.000217	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KITLG—testicular cancer	1.56e-05	0.000217	CbGpPWpGaD
Vandetanib—YES1—Immune System—FGFR3—testicular cancer	1.56e-05	0.000216	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—KIT—testicular cancer	1.56e-05	0.000216	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KITLG—testicular cancer	1.56e-05	0.000216	CbGpPWpGaD
Vandetanib—FYN—Disease—H2AFZ—testicular cancer	1.54e-05	0.000214	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KITLG—testicular cancer	1.54e-05	0.000214	CbGpPWpGaD
Vandetanib—FYN—Immune System—KITLG—testicular cancer	1.54e-05	0.000213	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—H2AFZ—testicular cancer	1.52e-05	0.000212	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STK11—testicular cancer	1.52e-05	0.00021	CbGpPWpGaD
Vandetanib—ERBB3—Disease—KIT—testicular cancer	1.5e-05	0.000209	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—KIT—testicular cancer	1.5e-05	0.000208	CbGpPWpGaD
Vandetanib—EGFR—Adaptive Immune System—KIT—testicular cancer	1.5e-05	0.000207	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KITLG—testicular cancer	1.47e-05	0.000204	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—H2AFZ—testicular cancer	1.47e-05	0.000204	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STK11—testicular cancer	1.46e-05	0.000203	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—FGFR3—testicular cancer	1.45e-05	0.000201	CbGpPWpGaD
Vandetanib—LCK—Adaptive Immune System—KIT—testicular cancer	1.44e-05	0.0002	CbGpPWpGaD
Vandetanib—YES1—Immune System—KIT—testicular cancer	1.43e-05	0.000198	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—HPGDS—testicular cancer	1.43e-05	0.000198	CbGpPWpGaD
Vandetanib—FYN—Disease—KITLG—testicular cancer	1.42e-05	0.000197	CbGpPWpGaD
Vandetanib—ABCC1—Disease—H2AFZ—testicular cancer	1.42e-05	0.000196	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KITLG—testicular cancer	1.4e-05	0.000195	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—FGFR3—testicular cancer	1.39e-05	0.000193	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KITLG—testicular cancer	1.36e-05	0.000188	CbGpPWpGaD
Vandetanib—EGFR—Disease—H2AFZ—testicular cancer	1.33e-05	0.000185	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MMP2—testicular cancer	1.33e-05	0.000185	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KITLG—testicular cancer	1.33e-05	0.000184	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—KIT—testicular cancer	1.33e-05	0.000184	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KITLG—testicular cancer	1.3e-05	0.000181	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—FGFR3—testicular cancer	1.3e-05	0.000181	CbGpPWpGaD
Vandetanib—LCK—Disease—H2AFZ—testicular cancer	1.29e-05	0.000178	CbGpPWpGaD
Vandetanib—LCK—Immune System—KITLG—testicular cancer	1.28e-05	0.000178	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—KIT—testicular cancer	1.28e-05	0.000177	CbGpPWpGaD
Vandetanib—EGFR—Disease—KITLG—testicular cancer	1.23e-05	0.00017	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—KIT—testicular cancer	1.19e-05	0.000166	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	1.19e-05	0.000165	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—FGFR3—testicular cancer	1.19e-05	0.000165	CbGpPWpGaD
Vandetanib—LCK—Disease—KITLG—testicular cancer	1.18e-05	0.000164	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—STK11—testicular cancer	1.18e-05	0.000164	CbGpPWpGaD
Vandetanib—LYN—Immune System—FGFR3—testicular cancer	1.16e-05	0.000161	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—FGFR3—testicular cancer	1.16e-05	0.000161	CbGpPWpGaD
Vandetanib—ABL1—Immune System—FGFR3—testicular cancer	1.16e-05	0.00016	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—FGFR3—testicular cancer	1.15e-05	0.000159	CbGpPWpGaD
Vandetanib—FYN—Immune System—FGFR3—testicular cancer	1.14e-05	0.000159	CbGpPWpGaD
Vandetanib—SRC—Disease—H2AFZ—testicular cancer	1.14e-05	0.000158	CbGpPWpGaD
Vandetanib—SRC—Immune System—KITLG—testicular cancer	1.13e-05	0.000157	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—H2AFZ—testicular cancer	1.12e-05	0.000156	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STK11—testicular cancer	1.12e-05	0.000155	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—H2AFZ—testicular cancer	1.1e-05	0.000152	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—FGFR3—testicular cancer	1.1e-05	0.000152	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—KIT—testicular cancer	1.09e-05	0.000152	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STK11—testicular cancer	1.09e-05	0.000152	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—KIT—testicular cancer	1.09e-05	0.000151	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—H2AFZ—testicular cancer	1.08e-05	0.00015	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STK11—testicular cancer	1.08e-05	0.000149	CbGpPWpGaD
Vandetanib—LYN—Immune System—KIT—testicular cancer	1.07e-05	0.000148	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—KIT—testicular cancer	1.07e-05	0.000148	CbGpPWpGaD
Vandetanib—ABL1—Immune System—KIT—testicular cancer	1.06e-05	0.000147	CbGpPWpGaD
Vandetanib—FYN—Disease—FGFR3—testicular cancer	1.06e-05	0.000146	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—KIT—testicular cancer	1.05e-05	0.000146	CbGpPWpGaD
Vandetanib—FYN—Immune System—KIT—testicular cancer	1.05e-05	0.000146	CbGpPWpGaD
Vandetanib—SRC—Disease—KITLG—testicular cancer	1.05e-05	0.000145	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—FGFR3—testicular cancer	1.04e-05	0.000145	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—STK11—testicular cancer	1.04e-05	0.000144	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KITLG—testicular cancer	1.03e-05	0.000143	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KITLG—testicular cancer	1.01e-05	0.00014	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—FGFR3—testicular cancer	1.01e-05	0.00014	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—KIT—testicular cancer	1.01e-05	0.00014	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KITLG—testicular cancer	9.95e-06	0.000138	CbGpPWpGaD
Vandetanib—EGFR—Immune System—FGFR3—testicular cancer	9.88e-06	0.000137	CbGpPWpGaD
Vandetanib—FYN—Disease—KIT—testicular cancer	9.69e-06	0.000135	CbGpPWpGaD
Vandetanib—ABCC1—Disease—FGFR3—testicular cancer	9.68e-06	0.000134	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—KIT—testicular cancer	9.57e-06	0.000133	CbGpPWpGaD
Vandetanib—LCK—Immune System—FGFR3—testicular cancer	9.52e-06	0.000132	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	9.34e-06	0.00013	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STK11—testicular cancer	9.29e-06	0.000129	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—KIT—testicular cancer	9.25e-06	0.000128	CbGpPWpGaD
Vandetanib—EGFR—Disease—FGFR3—testicular cancer	9.12e-06	0.000127	CbGpPWpGaD
Vandetanib—EGFR—Immune System—KIT—testicular cancer	9.07e-06	0.000126	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—H2AFZ—testicular cancer	9e-06	0.000125	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STK11—testicular cancer	8.95e-06	0.000124	CbGpPWpGaD
Vandetanib—ABCC1—Disease—KIT—testicular cancer	8.88e-06	0.000123	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HPGDS—testicular cancer	8.81e-06	0.000122	CbGpPWpGaD
Vandetanib—LCK—Disease—FGFR3—testicular cancer	8.79e-06	0.000122	CbGpPWpGaD
Vandetanib—LCK—Immune System—KIT—testicular cancer	8.74e-06	0.000121	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KITLG—testicular cancer	8.59e-06	0.000119	CbGpPWpGaD
Vandetanib—SRC—Immune System—FGFR3—testicular cancer	8.43e-06	0.000117	CbGpPWpGaD
Vandetanib—EGFR—Disease—KIT—testicular cancer	8.37e-06	0.000116	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KITLG—testicular cancer	8.28e-06	0.000115	CbGpPWpGaD
Vandetanib—LCK—Disease—KIT—testicular cancer	8.07e-06	0.000112	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—H2AFZ—testicular cancer	7.97e-06	0.000111	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STK11—testicular cancer	7.92e-06	0.00011	CbGpPWpGaD
Vandetanib—SRC—Disease—FGFR3—testicular cancer	7.78e-06	0.000108	CbGpPWpGaD
Vandetanib—SRC—Immune System—KIT—testicular cancer	7.74e-06	0.000107	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—FGFR3—testicular cancer	7.67e-06	0.000106	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—FGFR3—testicular cancer	7.51e-06	0.000104	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—FGFR3—testicular cancer	7.39e-06	0.000103	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KITLG—testicular cancer	7.33e-06	0.000102	CbGpPWpGaD
Vandetanib—SRC—Disease—KIT—testicular cancer	7.14e-06	9.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—KIT—testicular cancer	7.04e-06	9.77e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—KIT—testicular cancer	6.89e-06	9.57e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—KIT—testicular cancer	6.79e-06	9.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—STK11—testicular cancer	6.4e-06	8.88e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—FGFR3—testicular cancer	6.39e-06	8.86e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—FGFR3—testicular cancer	6.16e-06	8.54e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—KIT—testicular cancer	5.86e-06	8.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—KIT—testicular cancer	5.65e-06	7.84e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—FGFR3—testicular cancer	5.45e-06	7.56e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—KIT—testicular cancer	5e-06	6.94e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HPGDS—testicular cancer	4.75e-06	6.6e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STK11—testicular cancer	3.45e-06	4.79e-05	CbGpPWpGaD
